-

04:37:22 PM

LIVE Real Time RHHBY Stock Market News

RHHBY - Roche Holding AG

04/22/21 1:00 AM

OTC : RHHBY

Roche purchases shares in tender offer for GenMark Diagnostics, Inc.

Basel, 22 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Roche's wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding

RHEA-AI

neutral

04/21/21 1:00 AM

OTC : RHHBY

Roche reports solid results in the first quarter of 2021

Basel, 21 April 2021 Group sales increase 3% 1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales: Continued strong growth of new medicines (+20%) As expected, significant impact from biosimilars (CHF -1.6

RHEA-AI

neutral

04/16/21 1:00 AM

OTC : RHHBY

New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis

85% of treatment-naive, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS)

RHEA-AI

neutral

04/15/21 1:00 AM

OTC : RHHBY

Roche's Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)

More than twice as many babies (61% vs. 29%) were able to sit without support for at least five seconds after 24 months compared to 12 months of treatment Evrysdi increased survival and reduced need for permanent ventilation Evrysdi has proven efficacy across adults, children and babies 2 months

RHEA-AI

neutral

04/13/21 1:00 AM

OTC : RHHBY

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

? Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment Basel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved

RHEA-AI

very positive

04/12/21 1:20 PM

OTC : RHHBY

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application for Xolair (R) (omalizumab) prefilled syringe for self-injection across all approved U.S.

RHEA-AI

very positive

04/12/21 1:00 AM

OTC : RHHBY

Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration In a cohort of recently-infected asymptomatic patients, casirivimab and imdevimab reduced the overall risk of

RHEA-AI

neutral

04/08/21 1:00 AM

OTC : RHHBY

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio

EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA) OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Data for ENSPRYNG in

RHEA-AI

neutral

04/07/21 1:00 AM

OTC : RHHBY

Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types

Anti-p53 antibodies are antibodies that mistakenly target a patient's own tissues, leading to a growth of solid tumors. Screening for Anti-p53 helps to diagnose throat, bowel and breast cancers earlier, thereby increasing the chances that a patient responds to a treatment The Elecsys Anti-p53 could

RHEA-AI

neutral

03/31/21 1:00 AM

OTC : RHHBY

Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging

The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick diagnosis of acute infection allows physicians to decide faster on treatment for transplant patients

RHEA-AI

neutral

1 2 3 4 5 6 Next